TrialPath
Recruiting

Zephyr Valve Japan Post-Marketing Surveillance

NCT06332885 · Pulmonx Corporation
In plain English

Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.

About this study
This is a multicenter, prospective, observational surveillance across 20 centers in Japan enrolling 140 consecutive adult patients with hyperinflation of the lungs due to severe emphysema who are considered to be appropriate candidates for BLVR using Zephyr Endobronchial Valve (EBV, Pulmonx Corporation) and confirmed to have little to no collateral ventilation in the target lobe. Enrolled (consented) subjects will undergo a bronchoscopy procedure with the Chartis assessment to confirm that little to no collateral ventilation is present (CV- status) followed by EBV placement in the most diseased lobe. Subject will be hospitalized for a minimum of 3 nights for observation and followed up for 12 months. Subjects with collateral ventilation will be exited from the surveillance without treatment. The primary endpoint is incidence rate of pneumothorax at Day 45 post-index procedure. The effectiveness will be evaluated from Baseline to specified timepoint based on changes in lung function, exercise capacity, dyspnea and quality of life. A high-resolution computed tomography (HRCT) will be performed at Day 45 and Month 12 to determine Treated Lobe Volume Reduction (TLVR). Lung function will be assessed at Month 3, 6 and 12 by measuring post-bronchodilator forced expiratory volume in 1 second (FEV1), residual volume (RV) and 6 Minutes Walking Distance. The safety will be evaluated based on incident rate of treatment emergent adverse events through Month 12. Subjects will be required to complete a pulmonary rehabilitation program between Day 45 and Month 3 per local/national guidelines.
Eligibility criteria
Inclusion Criteria: 1. Patient is deemed eligible for BLVR using Zephyr Valve, as determined by their treating physician in accordance with Japanese guidelines and approved instruction for use. These include: * Recent respiratory rehabilitation completed within the last 6 months * Not actively smoking (for at least 4 months) * TLC ≥ 100% * RV ≥ 175% * FEV1 15-45% post-bronchodilator * 6MWD 100-500 m * mMRC score ≥ 2 * No coagulation disorder * No evidence of active respiratory infection 2. Patient has little to no collateral ventilation (CV-) between the target and ipsilateral lobe as confirmed by Chartis prior to undergoing BLVR. 3. Patient is willing and able to provide informed consent to allow data collection. Exclusion Criteria: None
Study design
Enrollment target: 140 participants
Age groups: adult, older_adult
Timeline
Starts: 2024-03-12
Estimated completion: 2028-03-31
Last updated: 2026-09-17
Interventions
Device: Zephyr Endobronchial Valve
Primary outcomes
  • • Incidence rate of pneumothorax at 45-days post-Zephyr Valve index procedure. (45-days post-Zephyr Valve index procedure)
Sponsor
Pulmonx Corporation · industry
Contacts & investigators
ContactMarie Barrigar · contact · marie.barrigar@pulmonx.com · +1 650-216-0128
InvestigatorNarinder Shargill, PhD · study_director, Pulmonx Corporation
All locations (17)
Tosei General HospitalRecruiting
Aichi, Japan
Gifu Prefectural Medical CenterRecruiting
Gifu, Japan
Kanagawa Cardio Chest CenterRecruiting
Kanagawa, Japan
Kanazawa University HospitalRecruiting
Kanazawa, Japan
St Marianna University HospitalRecruiting
Kawasaki, Japan
Matsusaka Civic HospitalRecruiting
Mie, Japan
Nagasaki University HospitalRecruiting
Nagasaki, Japan
Nagoya Medical CenterRecruiting
Nagoya, Japan
Okayama Medical CenterRecruiting
Okayama, Japan
Kinki Chuo Chest Medical CenterRecruiting
Osaka, Japan
Hokkaido University HospitalRecruiting
Sapporo, Japan
Tohoku University HospitalRecruiting
Sendai, Japan
Shiga University HospitalRecruiting
Shiga, Japan
Tokyo National HospitalRecruiting
Tokyo, Japan
Fujita Health University HospitalRecruiting
Toyoake, Japan
Dokkyo University Hospital (Pulmonary Medicine and Clinical Immunology)Not Yet Recruiting
Utsunomiya, Japan
Dokkyo University HospitalRecruiting
Utsunomiya, Japan